Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma

2021/10/08 by Jeremy Allan Goldfarb, Renata Ferrarotto, Neil D. Gross +8 · 8 citations
Medicine · #Nonmelanoma Skin Cancer Studies #Head and Neck Cancer Studies #Cancer Immunotherapy and Biomarkers

paper · doi:10.1136/bjophthalmol-2021-319417

Abstract

PURPOSE: To report on the outcomes of immunotherapy in patients with locally advanced periorbital squamous cell carcinoma. METHODS: We performed a retrospective chart review of seven consecutive patients with locally advanced periorbital cutaneous squamous cell carcinoma treated with anti-PD-1 immunotherapy. Treatments and therapeutic outcomes were reviewed. RESULTS: Of the seven patients, six were treated with cemiplimab, and one was treated with pembrolizumab. Five patients were treated with immunotherapy as neoadjuvant therapy before planned surgical resection; two patients received immunotherapy for treatment of advanced recurrent lesions deemed unresectable following multiple previous excisions and radiation therapy. In all seven patients, measurable clinical and/or radiologic response was observed. CONCLUSIONS: Our findings support the emerging role of anti-PD-1 immunotherapy in the management of locally advanced periorbital cutaneous squamous cell carcinoma.

Cited by

• Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. [europepmc]
• Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives. [europepmc]
• Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas. [europepmc]
• Review of recent advances in managing periocular skin malignancies. [europepmc]
• Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances. [europepmc]
• Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies. [europepmc]
• Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma: Systematic Literature Review and State of the Art. [europepmc]
• Efficacy of Neoadjuvant Cemiplimab Treatment for Cutaneous Squamous Cell Carcinoma-A Systematic Review. [europepmc]

Related

• An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma
• Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
• Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
• Pembrolizumab: review of its current therapeutic uses
• PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy